BioRegenx Announces Board Changes and Compensation Updates
Ticker: BRGX · Form: 8-K · Filed: Jul 15, 2024 · CIK: 1593184
| Field | Detail |
|---|---|
| Company | Bioregenx, INC. (BRGX) |
| Form Type | 8-K |
| Filed Date | Jul 15, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-change, executive-compensation
TL;DR
Board shakeup at BioRegenx, new director in, old one out. Compensation details also updated.
AI Summary
BioRegenx, Inc. announced on July 13, 2024, a change in its board of directors. Specifically, the company reported the departure of a director and the election of a new director, along with updates to its officer compensation arrangements.
Why It Matters
Changes in a company's board of directors and executive compensation can signal shifts in strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board changes and compensation adjustments can introduce uncertainty regarding future strategic direction and executive incentives.
Key Players & Entities
- BioRegenx, Inc. (company) — Registrant
- July 13, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 7407 Ziegler Road, Chattanooga, Tennessee 37421 (address) — Principal executive offices
FAQ
What specific changes were made to the board of directors?
The filing indicates the departure of a director and the election of a new director.
When was the earliest event reported in this filing?
The earliest event reported was on July 13, 2024.
What is the state of incorporation for BioRegenx, Inc.?
BioRegenx, Inc. is incorporated in Nevada.
Where are BioRegenx, Inc.'s principal executive offices located?
The principal executive offices are located at 7407 Ziegler Road, Chattanooga, Tennessee 37421.
What other items are covered in this 8-K filing besides director changes?
The filing also covers compensatory arrangements of certain officers.
Filing Stats: 359 words · 1 min read · ~1 pages · Grade level 12.2 · Accepted 2024-07-15 12:06:49
Filing Documents
- bioregenx_8k.htm (8-K) — 18KB
- 0001683168-24-004835.txt ( ) — 179KB
- fdit-20240713.xsd (EX-101.SCH) — 3KB
- fdit-20240713_lab.xml (EX-101.LAB) — 33KB
- fdit-20240713_pre.xml (EX-101.PRE) — 22KB
- bioregenx_8k_htm.xml (XML) — 3KB
02 Departure of Directors or Certain Officers; Election of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In conjunction with her retirement, Jody M. Walker resigned as a director of the Company effective as of July 13, 2024. Her departure was not a result of any disagreement with the Company, its Board or management.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioRegenx, Inc. (Registrant) Date: July 15, 2024 By: /s/ William Resides Name: William Resides Title: Chief Executive Officer 2